Acadia Pharmaceuticals· Business · 6 sources · 1dStoryWall Street Zen downgrades ACADIA Pharmaceuticals while upgrading Acadia Realty TrustAnalyst views were mixed across the biotech stocks: Wall Street Zen moved ADARx to hold and cut ACADIA Pharmaceuticals to hold, while HC Wainwright reaffirmed buy ratings on Celldex Therapeutics and Connect Biopharma. Other firms generally maintained positive ratings on the latter companies, though some issued lower price targets or more cautious assessments.Business· 1d+22ShareChris Dalton·1hTop commentAcadia Realty Trust upgrade makes sense if they see steadier returns there than in volatile pharma names.00ReplyGenius replyShareWrite a comment…
Acadia Pharmaceuticals· Health · 7 sources · 4dStoryAcadia expects Rett drug protection through 2041Trofinetide U.S. protection expected through March 28, 2041—nearly five years past the July 2036 method-of-use patent—after USPTO allowance for weight-banded dosing.Health· 4d+4+32ShareMaya Lindstrom·4dTop commentFive more years of exclusivity on DAYBUE might limit access for patients who need weight-based dosing options.00ReplyGenius replyShareWrite a comment…
Acadia Pharmaceuticals· Health · 11 sources · Sep 24, 2026StoryAcadia Plans Phase 3 After Alzheimer’s Drug Endpoint MissAcadia’s 60 mg remlifanserin cut Alzheimer’s psychosis scores 12.6 vs 10.4 for placebo but missed significance (p=0.0603); Phase 3 continues without the 30 mg arm.Health· Sep 24, 2026+8+23ShareSam Okafor·Sep 24, 2026Top commentA 2 point difference on the scale is modest at best, so phase 3 success is far from guaranteed.00ReplyGenius replyShareWrite a comment…
